Vol 16: Radium-223 in metastatic castration resistant prostate cancer.Reportar como inadecuado



 Vol 16: Radium-223 in metastatic castration resistant prostate cancer.


Vol 16: Radium-223 in metastatic castration resistant prostate cancer. - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Descargar gratis o leer online en formato PDF el libro: Vol 16: Radium-223 in metastatic castration resistant prostate cancer.
This article is from Asian Journal of Andrology, volume 16.AbstractIn 2004, docetaxel was approved for the treatment of metastatic castration-resistant prostate cancer mCRPC. For the next several years, there was a lull in drug approvals. However, from 2010 onwards, 5 additional therapies have been approved on the basis of showing a survival benefit in phase III studies. These agents include sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and most recently radium-223. Amongst radiopharmaceuticals currently used for advanced prostate cancer e.g. samarium-153 and strontium-89, radium-223 possesses several unique properties. As an alpha-emitting compound, the agent produces a high-energy output over a short range, facilitating selective destruction of tissue within the bone in the region of osteoblastic lesions while sparing surrounding normal tissue. The current review will outline biological rationale for radium-223 and also provide an overview of preclinical and clinical development of the agent. Rational sequencing of radium-223 and combinations, in the increasingly complex landscape of mCRPC will be discussed, along with factors influencing clinical implementation.



Autor: Vuong, Winston; Sartor, Oliver; Pal, Sumanta K

Fuente: https://archive.org/







Documentos relacionados